Protection of the vascular endothelium in experimental situations

Ružena SOTNÍKOVÁ 1, Jana NEDELČEVOVÁ 1, Jana NAVAROVÁ 1, Viera NOSÁLOVÁ 1, Katarína DRÁBIKOVÁ 1, Katalin SZÖCS 1, Peter KRÉNEK 2, Zuzana KYSIELOVÁ 1, Štefan BEZEK 1, Vladimír KNEZL 1, Ján DRÍMAL 1, Zuzana BROSKOVÁ 1, Viera KRISTOVÁ 3, Ludmila OKRUHLICOVÁ 4, Iveta BERNAČOVÁ 5, Viktor BAUER 1

1 Institute of Experimental Pharmacology & Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia
2 Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic
3 Faculty of Medicine, Comenius University, Bratislava, Slovak Republic
4 Institute of Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
5 Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic

ABSTRACT

One of the factors proposed as mediators of vascular dysfunction observed in diabetes is the increased generation of reactive oxygen species (ROS). This provides support for the use of antioxidants as early and appropriate pharmacological intervention in the development of late diabetic complications. In streptozotocin (STZ)-induced diabetes in rats we observed endothelial dysfuction manifested by reduced endothelium-dependent response to acetylcholine of the superior mesenteric artery (SMA) and aorta, as well as by increased endothelaemia. Changes in endothelium-dependent relaxation of SMA were induced by injury of the nitric oxide radical (•NO)-signalling pathway since the endothelium-derived hyperpolarising factor (EDHF)-component of relaxation was not impaired by diabetes. The endothelial dysfunction was accompanied by decreased •NO bioavailabity as a consequence of reduced activity of eNOS rather than its reduced expression. The results obtained using the chemiluminiscence method (CL) argue for increased oxidative stress and increased ROS production. The enzyme NAD(P)H-oxidase problably participates in ROS production in the later phases of diabetes. Oxidative stress was also connected with decreased levels of reduced glutathione (GSH) in the early phase of diabetes. After 10 weeks of diabetes, adaptational mechanisms probably took place because GSH levels were not changed compared to controls. Antioxidant properties of SMe1EC2 found in vitro were partly confirmed in vivo. Administration of SMe1EC2 protected endothelial function. It significantly decreased endothelaemia of diabetic rats and improved endothelium-dependent relaxation of arteries, slightly decreased ROS-production and increased bioavailability of •NO in the aorta. Further studies with higher doses of SMe1EC2 may clarify the mechanism of its endothelium-protective effect in vivo.

KEY WORDS: diabetes; ischaemia/reperfusion; pyridoindole antioxidants; SMe1EC2

Introduction

In the last decades, scientific research has revealed that deterioration of the endothelium with subsequent dam- age of smooth muscle reactivity results in generalised increase in vascular tone, platelet aggregation, thrombus formation, etc. The endothelium plays an important role in maintaining vascular homeostasis by synthesising and releasing several vasodilators, including prostacyclin, nitric oxide radical (•NO), and endothelium-derived hyperpolarising factor (EDHF) (Vanhoutte and Mombouli, 1996; Shimokawa, 1999). Endothelial dysfunction participates in the pathophysiology of various diseases like ath- erosclerosis, essential hypertension, diseases connected with ischaemia/reperfusion (I/R), rheumatoid arthritis, diabetic micro- and macrovasculopathies, etc. Among the mechanisms of the vascular dysfunction observed in these diseases, increased generation of reactive oxygen species (ROS) is emerging as a crucial factor. This pro- vides support for the use of antioxidants in preventing or alleviating the above mentioned diseases.

In the last decades, more than 70 new derivatives (Štolc et al., 2010) of the pyridoindole antioxidant stobadine – (–)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole, (Štolc et al., 1983; Horáková and Štolc, 1998) were synthesised and tested in the Institute
of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences. The main reason for synthesising new derivatives was to enlarge the antioxidative and anti-radical capacity of the parent substance and to eliminate the undesired α1-adrenolytic activity of stobadine (Štolc et al., 2006). SMelEC2, one of these new compounds, exhibited an increase in its antioxidative activity achieved by substitution of the methyl group in position 8 of stobadine by a methoxy group. This is explained by the increased ability of the aromatic circle to delocalise electron density from the stable nitrogen radical on indole. Substitution of nitrogen on the piperidine circle by an ethoxycarbonyl group prevented protonisation of this atom and led to loss of undesirable α1-adrenolytic activity and to decreased toxicity of SMelEC2 (Štolc et al., 2010; Štolc et al., 2006; Májeková et al., 2006, Ujházy et al., 2008). This was the reason why we selected this compound to study the possibility to improve endothelial dysfunction in several experimental models.

In our previous works, we documented endothelial dysfunction induced by different pathological situations in experimental models of ischaemia/reperfusion (I/R) (Sotníková et al., 1998; Nosálová et al., 2004; Szöcs, 2004; Sotníková et al., 2005; Nosálová et al., 2007), adjuvant arthritis (Sotníková et al., 2009), in spontaneously hypertensive rats in conditions of social stress (Sotníková et al., 2006; 2007), in hypertriglyceridaemic rats (Sotníková et al., 2008), etc. The common feature proved to be impaired endothelium-dependent relaxation of the arteries manifested by decreased response to acetylcholine. In the model of I/R of the abdominal aorta, we demonstrated I/R-induced reversible ultrastructural changes both in endothelial and smooth muscle cells, predominantly in the mitochondria. Participation of ROS in vascular injury was confirmed directly on using oxidative fluorescent microtopography (Szöcs et al., 2003), by observation of increased lipid peroxidation in homogenates of I/R aortae and by the ability of the antioxidant stobadine to protect the abdominal aorta against I/R-induced changes (Sotníková et al., 1998). Further, decreased release of NOX and increased activity of lysosomal enzymes – N-acetyl-β-D-glucosaminidase (NAGA) and acid phosphatase (APH) – in aortic homogenates were observed (Sotníková et al., 1999). Lysosomes consist of a lipoprotein membrane surrounding potent acid hydrolases able to degrade all known constituents of cells. Leakage of lysosomal enzymes into cells and the surrounding extracellular space has been implicated in the pathogenesis of tissue injury (Waters et al., 1992). Pretreatment of rats with stobadine reduced the NAGA and APH release evoked by I/R (Sotníková et al., 1997, Navarová et al., 1998).

The use of the model of mesenteric I/R in rats provided evidence of ROS contribution to I/R-induced endothelial dysfunction. By the method of luminol enhanced chemiluminiscence (CL) we demonstrated increased generation of ROS in SMA tissue after 60-min ischaemia followed by 30-min reperfusion of the rat mesentery, which resulted in injury of both the NO and EDHF-endothelial relaxing systems of the SMA (Sotníková et al., 2005).

**Endothelial dysfunction in experimental diabetes**

Although the aetiopathology of vascular disorders in long lasting diabetes is not fully understood, it has been suggested that abnormal vascular function may underlie many of the associated vasculopathies. These are major causes of disability and death in patients with type 1 diabetes mellitus (Yan et al., 2003). Under physiological conditions, glucose is transported into the cells by means of glucose transporters. Transport of glucose to the endothelium and smooth muscle cells is not insulin-dependent, thus in the case of hyperglycaemia intracellular concentration of glucose in these cells increases and can induce their injury.

Reduction in endothelium-dependent relaxation is a common feature known to occur in both conduit and resistance arteries of experimental diabetic animals. Moreover, increased responsiveness of vessels to contractile agents in diabetes mellitus was also reported. Among the proposed mechanisms of vascular dysfunction in diabetes, the increased generation of ROS is emerging as a crucial factor. The above facts provide support for the use of antioxidants in prevention of diabetic complications (Karasu et al., 1997, Afanasjev, 2010).

In our previous experiments, we found impaired endothelial function induced by long-lasting streptozotocin (STZ)-induced diabetes in rats (Sotníková et al., 1999a). Dietary supplementation of the pyridoindole antioxidant stobadine reduced this impairment (Sotníková et al., 2001). The long-lasting hyperglycaemia had a detrimental yet reversible effect on the structure of the aorta, which was reduced by administration of antioxidants (Okruhlicová et al., 2001).

The experimental model of STZ-induced diabetes was used to study the ability of the pyridoindole antioxidant SMelEC2 to prevent or delay the onset of diabetic vasculopathy. Diabetes was induced by STZ (30 mg/kg i.p.) administered for three consecutive days to male rats. Administration of repeated low doses of STZ is connected with an autoimmune process, insulinitis and slow death of pancreatic beta-cells, a process mimicking human diabetes type 1 (Lukic et al., 1991). Changes in vascular function (the aorta and SMA) and of markers of endothelial injury were studied after 5 and 10 weeks from the last dose of STZ.

The first changes in vascular endothelial function could be observed 5 weeks after induction of diabetes and were demonstrated by increased endothelaemia (Table 1) and diminished endothelium-dependent relaxation of SMA to acetylcholine (Figure 1a). After prolonging the duration of diabetes to 10 weeks, the endothelial injury deepened and was observed also in the aorta (Zúrová et al., 2006).

The reduced endothelium-dependent response can be mediated by several mechanisms: decreased bioavailability of NO, impaired diffusion of NO to smooth muscle cells, their decreased sensitivity or increased production of constrictory factors produced by the endothelium (Dai et al., 1993). In our experiments we demonstrated
In contrast to the results of Wigg et al. (2001), we did not find any changes in acetylcholine-induced relaxation of arterial preparations after blockade of the endothelial NO synthase (eNOS) inhibitor L-NAME and with the endothelial NO synthase (eNOS) inhibitor indomethacin to obtain EDHF-induced relaxation after blockade of the activity. The enzyme eNOS is localised in caveolae where it is coupled with caveolin-1, a 22kDa protein, which is a physiological inhibitor of eNOS. After increasing intracellular calcium concentrations in endothelial cells, the complex caveolin-1 with eNOS breaks and eNOS is activated (Garcia-Cardena et al., 1997; Bucci et al., 2000). Using Western blot analysis, we did not find changes in eNOS expression, however expression of caveolin-1 was increased appr. to 140% of controls (Dai et al., 2003). Moreover, peroxinitrite is also metabolised to a highly reactive hydroxyl radical (Beckman et al., 1990), which contributes to diabetes-induced endothelial dysfunction (Dai et al., 1993). Long-lasting hyperglycaemia is the most important factor responsible for endothelial dysfunction in diabetes. Cosentino et al. (2003) observed reduced

Diabetes-induced changes in *NO-availability can be caused by changed production of *NO. Adequate *NO production depends on intact function of eNOS, with sufficiency of cofactors and substrates. Depressed production of *NO can be the result of either decreased eNOS expression or its activity. The enzyme eNOS is localised in caveolae where it is coupled with caveolin-1, a 22kDa protein, which is a physiological inhibitor of eNOS. After increasing intracellular calcium concentrations in endothelial cells, the complex caveolin-1 with eNOS breaks and eNOS is activated (Garcia-Cardena et al., 1997; Bucci et al., 2000). Using Western blot analysis, we did not find changes in eNOS expression, however expression of caveolin-1 was increased appr. to 140% of controls (Dai et al., 2003). Moreover, peroxinitrite is also metabolised to a highly reactive hydroxyl radical (Beckman et al., 1990), which contributes to diabetes-induced endothelial dysfunction (Dai et al., 1993). Long-lasting hyperglycaemia is the most important factor responsible for endothelial dysfunction in diabetes. Cosentino et al. (2003) observed reduced

Table 1. Effect of SMe1EC2 on endothelaemia, on basal chemiluminescence and on NOx and GSH levels in the aorta after 5 weeks of diabetes.

| Group       | Endothelaemia | CL | NOx | GSH       |
|-------------|---------------|----|-----|-----------|
| C           | 2.29 ± 0.29   | 0.573±0.13 | 108.82±11.2 | 4.34±0.70 |
| D           | 3.71 ± 0.25*  | 1.153±0.18 | 61.90±14.42 | 1.70±0.66*|
| D – SMe1EC2 | 2.05 ± 0.51*  | 0.925±0.12 | 89.85±5.02  | 2.78±0.62 |

C – control group; D – diabetic group, D-SMe1EC2 – diabetic rats treated with SMe1EC2. Endothelaemia is expressed in the cell number/10μl blood, chemiluminescence (CL) as AUC (area under the curve) in mV/min/mg aortic tissue, NOx levels in nmol/mg protein, levels of reduced glutathione (GSH) in μg/mg protein. Results are means ± S.E.M., n= 5–9,* p<0.05 versus control. + p<0.05 versus diabetes.

Figure 1. Effect of SMe1EC2 on endothelium-dependent relaxation of the superior mesenteric artery (SMA) ex vivo. Acetylcholine-induced responses of the phenylephrine (1μmol/l)-precontracted rings of SMA from control rats (C), control rats treated with 10mg/kg SMe1EC2 (C-SMe1EC2), diabetic rats (D), diabetic rats treated with SMe1EC2 (D-SMe1EC2). A – before blockade of eNOS with L-NAME and of prostaglandin synthesis with indomethacin; B – after blockade of eNOS with L-NAME and of prostaglandin synthesis with indomethacin. Data are means±S.E.M. of 8 experiments. ***p<0.001 versus C.
levels of NOx caused by incubation of endothelial cells in solutions containing high concentrations of glucose. Similarly in our in vitro experiments, incubation of the aorta in the solution containing high concentration of glucose resulted in reduced endothelium-dependent relaxation (Figure 2a). We suggest that this is connected with oxidative stress since on using CL we found increased ROS production in these aortic preparations (Figure 2b).

One of the sources of ROS production is activation of protein kinase C (PKC), which activates NAD(P)H-oxidase producing high amounts of superoxide in vessels (Cosentino et al., 2003). NAD(P)H-oxidase is a dominant source of superoxide in the vessels. It is a multicomponent enzyme found in phagocytes, endothelial and smooth muscle cells and in fibroblasts of vascular adventitia. It consists of the main catalytic subunit gp91phox (in vessels nox2) and of regulatory subunits p22phox, p47phox, p67phox, p40phox and GTPase Rac2. The subunits gp91phox and p22phox supply the transport of electrons from NAD(P)H to O2. Homologues of gp91phox were identified in vessels and they are termed nox1-5. Up to 45–56% they are identical with gp91phox (Babior, 1999). In our experiments, we found increased ROS production already after 5 weeks of diabetes (Table 1) but no changes in mRNA expression of subunits nox1 and nox4. One of the explanations could be that in the early phases of diabetes enzymatic NAD(P)H-oxidase activity is increased by accelerated association of individual components without increased expression of catalytic subunits. However Wendt et al. (2005) observed increased activity simultaneously with increased nox1 expression after 8 weeks of diabetes. Another explanation could be that in the early phases of diabetes an increased production of superoxide in vessels may be the consequece of increased expression of nox2 (Hink et al., 2001). It thus seems that individual catalytic subunits of NAD(P)H-oxidase are exprimed at different time intervals, in different types of cells and they may also possess different functions. While nox2 subunit is responsible for ROS production in endothelial cells, nox1 subunit is a source of ROS in vascular smooth muscle cells. Angiotensin II increases nox1 expression, yet it has no effet on nox4 subunit (Mollnau et al., 2002). On the other hand, TNF-α increases nox4 sub-unit and does not influence nox1 expression (Moe et al., 2006). In our experiments, we observed increased nox4 expression when diabetes lasted a very long time, i.e. 5 months (p<0.05), while nox1 expression was not changed. Moreover, nox4 expression was many times higher than nox1 expression. We suggest that under conditions of our experimental model, nox4 plays a more important role.

Oxidative stress can result also from reduced activity of antioxidative systems. We observed decreased levels of reduced glutathione (GSH) after 5 weeks of diabetes (from control values of 5.34 ± 0.70 to 2.70 ± 0.76 μg/mg protein, p<0.05) which is in agreement with results of Tachi et al. (2001) and Yue et al. (2003). Changes in GSH levels probably result from increased ROS production induced by hyperglycaemia, which is in accordance with the observation of GSH depletion in vascular cells incubated with a high concentration of glucose (Urata et al., 1996). On the

---

**Figure 2.** Effect of SMe1EC2 on endothelial dysfunction induced by a high concentration of glucose in vitro. C – control preparations incubated in Krebs solution, GLU – preparations incubated in Krebs solution containing 44 mmol/l glucose, GLU-SMe1EC2 – preparations incubated in Krebs solution containing 44 mmol/l glucose and 10 μmol/l SMe1EC2. A – responses of phenylephrine (1 μmol/l)-precontracted rings of the aorta to acetylcholine: 8 – chemiluminiscence expressed as AUC (area under the curve) in mV/min/mg of wet aortic tissue. Data are means±S.E.M. of 6 experiments. *p<0.05, **p<0.01 versus C.
other hand, after 10 weeks of diabetes GSH concentration in the aorta was not changed (Zúrová-Nedelčevová et al., 2006). We propose that unchanged GSH levels in the aorta may reflect adaptation of the organism to chronic oxidative stress in the later phase of diabetes.

**Effect of SMe1EC2**

On using the described experimental model, an endothelium-protective effect of the antioxidant stobadine was observed. This finding confirmed the assumption of the important role of ROS in aetiopathology of diabetes-induced endothelial dysfunction (Sotníková et al., 2006a).

In the same model of STZ-diabetes, we further studied the effect of the stobadine derivative SMe1EC2 administered in the dose of 10 mg/kg every second day. A beneficial effect of SMe1EC2 on the vascular endothelium was found in our *in vitro* experiments, in which the aortal rings were incubated in a solution with a high concentration of glucose. The decreased endothelium-dependent relaxation was restored by this antioxidant (Figure 2). Searching for possible mechanisms of the SMe1EC2 protective effect, we found that it had no effect on basal tone of the arterial preparations or on contraction induced by depolarisation. It did not influence the concentration-response curves of phenylephrine or serotonin, indicating no effect on α1-adrenergic or 5-hydroxytryptamine receptors. Moreover, SMe1EC2 did not affect responses of the isolated aorta to the M3-agonist acetylcholine. Thus we propose that the endothelium-protective effect of SMe1EC2 is mediated by its antioxidant activity found also in the 1,1-diphenyl-2-picrylhydrazyl radical – (DPPH) test (Nosáľová et al., 2010). With pD2 value of 5.67, SMe1EC2 exhibited a DPPH radical-scavenging activity higher than did stobadine. Indeed, under *in vitro* conditions, this compound suppressed production of ROS evoked by mesenteric I/R (Nosáľová et al., 2010) and significantly reduced contraction of the aorta induced by ROS released from activated neutrophils (Bauer et al., 2008) (Figure 3).

We further found that *in vivo* administration of 10 mg/kg SMe1EC2 protected endothelial function. It significantly decreased endothelaemia of diabetic rats (Table 1) and improved endothelium-dependent relaxation of the aorta (Zúrová-Nedelčevová et al., 2006) and SMA without effect on the EDHF component (Figure 1). Therefore we assumed that this compound affected the *NO*-signalling pathway. Administration of SMe1EC2 slightly increased biological availability of *NO* in the aorta (Table 1), but it did not influence expression of eNOS or of caveolin-1. One of the explanations is that by its antioxidant properties SMe1EC2 inactivated ROS and thus increased *NO* bioavailability. This assumption was based also on the results of our *in vitro* experiments in which this compound intensively reduced CL increased by high glucose incubation and simultaneously protected endothelium-dependent relaxation of the aorta (Figure 2). In *in vivo* conditions, we observed a tendency of SMe1EC2 to decrease spontaneous ROS production and to increase levels of GSH in the aorta of diabetic rats (Table 1). These results may indicate that the dose of 10 mg/kg SMe1EC2 was not sufficient to observe all antioxidant properties *in vivo*. Further studies with higher doses of SMe1EC2 may clarify the mechanism of its endothelium-protective effect in STZ-diabetes in rats.

**Acknowledgement**

The authors would like to thank Dr. M. Kouřilová for correcting the English and for her critical reading of the manuscript. The authors thank Mrs. Dytrichová, Kollárová, Puškášová, Srnová, and Stojkovičová for their excellent technical assistance. This work was supported by grants VEGA No. 2/0050/09, 2/0086/08 and APVV-51-017905.

**REFERENCES**

Afanasjev I. (2010). Signaling of reactive oxygen and nitrogen species in Diabetes mellitus. *Oxid Med Cell Longev* 3: 361–373.

Babior BM. (1999). NADPH-oxidase. An update. *Blood* 93: 1464–1476.

Bauer V, Sotníková R and Gergel D. (2008). Comparison of the effects of activated neutrophils with the action of reactive oxygen species (ROS) on rat aortic smooth muscle (RASM). *Prague Med Report* 109: 13–14.

Beckman JS, Beckman TW, Chen J, Marshall PA and Freeman BA. (1990). Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 87: 1620–1624.
Bucci M, Grattan JP, Rudic RD, Aceredo L, Roviezzo F, Cinino G and Sessa WC. (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362–1367.

Bucci M, Roviezzo F, Brancalöne V, Lin MI, Di Lorenzo A, Cicala C, Pinto A, Sessa WC, Farneti S, Fiorucci S and Cinino G. (2004). Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an endothelial expression. Arterioscler Thromb Vasc Biol 24: 721–726.

Cosentino S, Eto M, De Paula P, van der Loo B, Bachschmid M, Ullrich V, Kuro- roedov A, Gatti CD, Joch H, Volpe M and Lüscher TF. (2003). High glucose causes upregulation of cyclooxygenase-2 and alters prostanooid profile in human endothelial cells. Circulation 107: 1017–1023.

Dai FX, Diederich A, Skopek J and Diederich D. (1993). Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 4: 1327–1336.

García-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP and Sessa WC. (1997). Dissecting the role of NOX2 in diabetes-induced alterations induced by ischaemia/reperfusion. J Mol Med 75: 661–670.

Mráz P. (2001). Effect of stobadine and arginine on the structure of diabetic aorta. 102: 35–40, Institute of Normal and Pathological Physiology SAS, Bratislava.
Waters PJ, Flyn MD, Corrall RJM and Pennock CA. (1992). Increases in plasma lysosomal enzymes in type 1 (insulin-dependent) diabetes mellitus: relationship to diabetic complications and glycaemic control. *Diabetologia* 35: 991–995.

Wendt MC, Daider A, Kleschyov AL, Mülch A, Sydow K, Schulz E, Chen K, Keaney JF, Lassegue B, Walter U, Griendling KK and Munzel T. (2005). Differential effect of diabetes on the expression of the gp91phox homologues nox1 and nox4. *Free Radic Biol Med* 39: 381–391.

Wigg SJ, Tare M, Tonta MA, O’Brien RC, Meredith IT and Parkington HC. (2001). Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. *Am J Physiol Heart Circ Physiol* 281: H232–H240.

Yan SF, Ramasamy R, Naka Y and Schmidt AM. (2003). Glycation, inflammation, and RAGE. A scaffold for the microvascular complications of diabetes and beyond. *Circ Res* 93: 1159–1169.

Yue KKM, Lee KW, Chan KKC, Leung KSY, Leung AWIN and Cheng CHK. (2006). Danshen prevents the occurrence of oxidative stress in the eye and aorta of diabetic rats without affecting the hyperglycemic state. *J Ethnopharmacol* 106: 136–141.

Zúrová-Nedelčevová J, Navarová J, Drábiková K, Jančinová V, Petríková M, Bernátová J, Kristová V, Šnirc V, Nosálová V and Sotníková R. (2006). Participation of reactive oxygen species in diabetes-induced endothelial dysfunction. *Neuroendocrinol Lett* 27: 68–171.